Hyponatraemia and vasopressin in heart failure: markers or mediators?

被引：10
作者：
Konstam, Marvin A. [1 ]
Udelson, James E.
机构：
[1] Tufts Med Ctr, CardioVasc Ctr, Boston, MA 02111 USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2011年 / 13卷 / 03期
关键词：
PLASMA ARGININE VASOPRESSIN; SYSTOLIC DYSFUNCTION; CONTROLLED-TRIAL; ORAL TOLVAPTAN; DOUBLE-BLIND; ANTAGONIST; MULTICENTER; NONPEPTIDE; SODIUM;
D O I：
10.1093/eurjhf/hfq236
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：242 / 244
页数：3
相关论文
共 20 条
[1]   Aquaretic efect of Lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients [J].
Abraham, WT ;
Shamshirsaz, AA ;
McFann, K ;
Oren, RM ;
Schrier, RW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) :1615-1621
[2]   Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study [J].
Aronson, Doron ;
Verbalis, Joseph G. ;
Mueller, Matthias ;
Krum, Henry .
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (03) :327-336
[3]   Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure [J].
Costello-Boerrigter, LC ;
Smith, WB ;
Boerrigter, G ;
Ouyang, J ;
Zimmer, CA ;
Orlandi, C ;
Burnett, JC .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (02) :F273-F278
[4]   Non-peptide arginine-vasopressin antagonists: the vaptans [J].
Decaux, Guy ;
Soupart, Alain ;
Vassart, Gilbert .
LANCET, 2008, 371 (9624) :1624-1632
[5]   COMPARISON OF NEUROENDOCRINE ACTIVATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION WITH AND WITHOUT CONGESTIVE-HEART-FAILURE - A SUBSTUDY OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) [J].
FRANCIS, GS ;
BENEDICT, C ;
JOHNSTONE, DE ;
KIRLIN, PC ;
NICKLAS, J ;
LIANG, CS ;
KUBO, SH ;
RUDINTORETSKY, E ;
YUSUF, S .
CIRCULATION, 1990, 82 (05) :1724-1729
[6]   Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial [J].
Gheorghiade, M ;
Gattis, WA ;
O'Connor, CM ;
Adams, KF ;
Elkayam, U ;
Barbagelata, A ;
Ghali, JK ;
Benza, RL ;
McGrew, FA ;
Klapholz, M ;
Ouyang, J ;
Orlandi, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16) :1963-1971
[7]   Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure -: Results from a double-blind, randomized trial [J].
Gheorghiade, M ;
Niazi, I ;
Ouyang, J ;
Czerwiec, F ;
Kambayashi, J ;
Zampino, M ;
Orlandi, C .
CIRCULATION, 2003, 107 (21) :2690-2696
[8]   Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry [J].
Gheorghiade, Mihai ;
Abraham, William T. ;
Albert, Nancy M. ;
Stough, Wendy Gattis ;
Greenberg, Barry H. ;
O'Connor, Christopher M. ;
She, Lilin ;
Yancy, Clyde W. ;
Young, James ;
Fonarow, Gregg C. .
EUROPEAN HEART JOURNAL, 2007, 28 (08) :980-988
[9]   Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials [J].
Gheorghiade, Mihai ;
Konstam, Marvin A. ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Maggioni, Aldo P. ;
Swedberg, Karl ;
Udelson, James E. ;
Zannad, Faiez ;
Cook, Thomas ;
Ouyang, John ;
Zimmer, Christopher ;
Orlandi, Cesare .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12) :1332-1343
[10]   INCREASED PLASMA ARGININE VASOPRESSIN LEVELS IN PATIENTS WITH CONGESTIVE HEART-FAILURE [J].
GOLDSMITH, SR ;
FRANCIS, GS ;
COWLEY, AW ;
LEVINE, TB ;
COHN, JN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1983, 1 (06) :1385-1390
12